LB-1908 is under clinical development by Legend Biotech and currently in Phase I for Adenocarcinoma Of The Gastroesophageal Junction. According to GlobalData, Phase I drugs for Adenocarcinoma Of The Gastroesophageal Junction have an 87% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how LB-1908’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
LB-1908 overview
LB-1908 (LCAR-C18S) is under development for the treatment of relapsed or refractory gastric cancer, esophageal cancer, gastro-esophageal junction adenocarcinoma and metastatic adenocarcinoma pancreas. The therapy comprises of autologous T-cells genetically engineered to express chimeric antigen receptors (CAR) targeting cells expressing claudin18.2 (CLDN18.2). It is administered through intravenous route. It was also under development for pancreatic cancer, gastric cancer and esophageal cancer.
Legend Biotech overview
Legend Biotech, a subsidiary of Genscript Biotech Corp, develops, manufactures, and commercializes novel therapies to treat life-threatening diseases. The company develops advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell and natural killer (NK) cell-based immunotherapy. Legend Biotech also operates research and development sites. The company operates in the Americas and Europe. Legend Biotech is headquartered in Piscataway, New Jersey, the US.
For a complete picture of LB-1908’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
